Venetoclax, CLAD/LDAC and azacitdine in older AML patients

Cladribine + LDAC + venetoclax alternated with azacitidine + venetoclax in older patients with AMLПодробнее

Cladribine + LDAC + venetoclax alternated with azacitidine + venetoclax in older patients with AML

Venetoclax and azacitidine for AML ineligible for standard inductionПодробнее

Venetoclax and azacitidine for AML ineligible for standard induction

Results from Venetoclax Added to CLAD Combo for Older Patients w/ #AML | Tapan Kadia, MD | ASH 2023Подробнее

Results from Venetoclax Added to CLAD Combo for Older Patients w/ #AML | Tapan Kadia, MD | ASH 2023

The role of venetoclax in older patients with AMLПодробнее

The role of venetoclax in older patients with AML

AML: Optimizing Selection and Use of Venetoclax + AzacitidineПодробнее

AML: Optimizing Selection and Use of Venetoclax + Azacitidine

Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 yearsПодробнее

Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 years

allo-SCT improves survival following venetoclax and azacitidine therapy in AMLПодробнее

allo-SCT improves survival following venetoclax and azacitidine therapy in AML

Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungalsПодробнее

Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungals

Venetoclax and azacitidine in older patients with AMLПодробнее

Venetoclax and azacitidine in older patients with AML

VEN-A-QUI: low-dose cytarabine or azacitidine+venetoclax and quizartinib in older patients with AMLПодробнее

VEN-A-QUI: low-dose cytarabine or azacitidine+venetoclax and quizartinib in older patients with AML

Venetoclax plus azacitidine for higher-risk MDSПодробнее

Venetoclax plus azacitidine for higher-risk MDS

IMGN632 plus venetoclax and/or azacitidine for patients with CD123-positive AMLПодробнее

IMGN632 plus venetoclax and/or azacitidine for patients with CD123-positive AML

Treating older patients with AML in 2020: What is new and promising?Подробнее

Treating older patients with AML in 2020: What is new and promising?

For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”Подробнее

For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”

Venetoclax and azacitidine for young patients with AMLПодробнее

Venetoclax and azacitidine for young patients with AML

Venetoclax & azacitidine for AML in 2020Подробнее

Venetoclax & azacitidine for AML in 2020

Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients ...Подробнее

Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients ...

Venetoclax + azacitidine in unfit patients with AMLПодробнее

Venetoclax + azacitidine in unfit patients with AML

Venetoclax for elderly AML patientsПодробнее

Venetoclax for elderly AML patients

CLAD-LDAC-Ven induction therapy in AML: insights from a Phase II trialПодробнее

CLAD-LDAC-Ven induction therapy in AML: insights from a Phase II trial